165 related articles for article (PubMed ID: 31291629)
1. Aripiprazole Combined with Lamotrigine in the Treatment of a Treatment-Resistant Schizophrenic Patient with Tardive Dyskinesia and Supersensitivity Psychosis.
Peretti CS; Chouinard G
Psychother Psychosom; 2019; 88(5):313-314. PubMed ID: 31291629
[No Abstract] [Full Text] [Related]
2. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of low-Dose Aripiprazole to Treat Clozapine-Associated Tardive Dystonia in a Patient with Schizophrenia].
Huh L; Lee BJ
Turk Psikiyatri Derg; 2017; 28(3):208-211. PubMed ID: 28936820
[TBL] [Abstract][Full Text] [Related]
4. Recent Discussions on Dopamine Supersensitivity Psychosis: Eight Points to Consider When Diagnosing Treatment-Resistant Schizophrenia.
Kanahara N; Kimura H; Oda Y; Ito F; Iyo M
Curr Neuropharmacol; 2021; 19(12):2214-2226. PubMed ID: 33550976
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
[TBL] [Abstract][Full Text] [Related]
6. A Review of Differences in Clinical Characteristics between Tardive Syndrome Induced or Improved by Aripiprazole Treatment.
Chen YW; Tseng PT
Acta Neurol Taiwan; 2016 Sep; 25(3):88-94. PubMed ID: 27854086
[TBL] [Abstract][Full Text] [Related]
7. Dopamine supersensitivity psychosis and dopamine partial agonist: a retrospective survey of failure of switching to aripiprazole in schizophrenia.
Takase M; Kanahara N; Oda Y; Kimura H; Watanabe H; Iyo M
J Psychopharmacol; 2015 Apr; 29(4):383-9. PubMed ID: 25735995
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
[TBL] [Abstract][Full Text] [Related]
9. Addition of lamotrigine to clozapine in inpatients with chronic psychosis.
Heck AH; de Groot IW; van Harten PN
J Clin Psychiatry; 2005 Oct; 66(10):1333. PubMed ID: 16259551
[No Abstract] [Full Text] [Related]
10. Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management.
Salem H; Pigott T; Zhang XY; Zeni CP; Teixeira AL
Expert Rev Neurother; 2017 Sep; 17(9):883-894. PubMed ID: 28750568
[TBL] [Abstract][Full Text] [Related]
11. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol.
Oosthuizen PP; Emsley RA; Maritz JS; Turner JA; Keyter N
J Clin Psychiatry; 2003 Sep; 64(9):1075-80. PubMed ID: 14628983
[TBL] [Abstract][Full Text] [Related]
12. Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia: a 24-week follow-up study.
Chan CH; Chan HY; Chen YC
Int Clin Psychopharmacol; 2018 May; 33(3):155-162. PubMed ID: 29324468
[TBL] [Abstract][Full Text] [Related]
13. Aripiprazole-induced tardive dyskinesia in patients with schizophrenia: A case report of twins.
She S; Kuang Q; Zheng Y
Schizophr Res; 2018 Jul; 197():564-565. PubMed ID: 29128325
[No Abstract] [Full Text] [Related]
14. Meta-analysis and systematic review of vesicular monoamine transporter (VMAT-2) inhibitors in schizophrenia and psychosis.
Connolly A; Wallman P; Dzahini O; Howes O; Taylor D
Psychopharmacology (Berl); 2024 Feb; 241(2):225-241. PubMed ID: 38238580
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
[TBL] [Abstract][Full Text] [Related]
16. Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference.
Stacy M; Sajatovic M; Kane JM; Cutler AJ; Liang GS; O'Brien CF; Correll CU
Mov Disord; 2019 Aug; 34(8):1203-1209. PubMed ID: 31234240
[TBL] [Abstract][Full Text] [Related]
17. Aripiprazole induced Impulse Control Disorders: Where do we stand?
Mahapatra A; Sharma P; Sagar R
Asian J Psychiatr; 2016 Oct; 23():128-130. PubMed ID: 27969070
[No Abstract] [Full Text] [Related]
18. Combination therapy of electroconvulsive therapy and aripiprazole for dopamine supersensitivity psychosis.
Kanahara N; Hirabayashi M; Mamada T; Nishimoto M; Iyo M
Schizophr Res; 2018 Dec; 202():398-400. PubMed ID: 29937327
[No Abstract] [Full Text] [Related]
19. Tardive Dyskinesia and Covert Dyskinesia with Aripiprazole: A Case Series.
Patra S
Curr Drug Saf; 2016; 11(1):102-3. PubMed ID: 26391425
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model.
Hard ML; Mills RJ; Sadler BM; Wehr AY; Weiden PJ; von Moltke L
CNS Drugs; 2017 Jul; 31(7):617-624. PubMed ID: 28597226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
